RASJ
MCID: RHM021
MIFTS: 49

Rheumatoid Arthritis, Systemic Juvenile (RASJ)

Categories: Bone diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Rheumatoid Arthritis, Systemic Juvenile

MalaCards integrated aliases for Rheumatoid Arthritis, Systemic Juvenile:

Name: Rheumatoid Arthritis, Systemic Juvenile 57 29 55 40 72
Rheumatoid Arthritis, Systemic Juvenile, Susceptibility to 57 13 6
Juvenile-Onset Still Disease 74 72
Systemic-Onset Juvenile Idiopathic Arthritis 59
Systemic Onset Juvenile Chronic Arthritis 72
Systemic Juvenile Rheumatoid Arthritis 57
Rheumatoid Arthritis Systemic Juvenile 74
Systemic Polyarthritis 59
Arthritis, Juvenile 44
Systemic-Onset Jia 59
Stills Disease 55
Still Disease 59
Rasj 74

Characteristics:

Orphanet epidemiological data:

59
systemic-onset juvenile idiopathic arthritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:



External Ids:

OMIM 57 604302
MeSH 44 D001171
ICD10 via Orphanet 34 M08.2
UMLS via Orphanet 73 C0087031 C1384600
Orphanet 59 ORPHA85414
MedGen 42 C1858558
UMLS 72 C0087031 C1384600 C1858558

Summaries for Rheumatoid Arthritis, Systemic Juvenile

UniProtKB/Swiss-Prot : 74 Rheumatoid arthritis systemic juvenile: An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.

MalaCards based summary : Rheumatoid Arthritis, Systemic Juvenile, also known as rheumatoid arthritis, systemic juvenile, susceptibility to, is related to adult-onset still's disease and rheumatoid factor-negative juvenile idiopathic arthritis. An important gene associated with Rheumatoid Arthritis, Systemic Juvenile is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and skin, and related phenotypes are fever and joint swelling

More information from OMIM: 604302

Related Diseases for Rheumatoid Arthritis, Systemic Juvenile

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile Juvenile Rheumatoid Arthritis

Diseases related to Rheumatoid Arthritis, Systemic Juvenile via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
# Related Disease Score Top Affiliating Genes
1 adult-onset still's disease 33.1 MIF IL6 IL1R1
2 rheumatoid factor-negative juvenile idiopathic arthritis 32.7 IL2RB HLA-DRB1
3 juvenile rheumatoid arthritis 32.6 IL6 IL1R1 HLA-DRB1
4 mixed connective tissue disease 30.2 IL6 HLA-DRB1
5 rheumatoid vasculitis 29.8 MIF HLA-DRB1
6 arthritis 29.6 MIF LACC1 IL6 HLA-DRB1
7 cryopyrin-associated periodic syndrome 29.5 IL6 IL1R1
8 rheumatic disease 28.8 IL2RB IL1R1 HLA-DRB1
9 sarcoidosis 1 28.7 IL2RB HLA-DRB1
10 rheumatoid arthritis 28.7 MIF LACC1 IL6 IL1R1 HLA-DRB1
11 enthesitis-related juvenile idiopathic arthritis 11.8
12 rheumatoid factor-positive polyarticular juvenile idiopathic arthritis 11.7
13 polyarticular onset juvenile idiopathic arthritis 11.6
14 systemic onset juvenile idiopathic arthritis 11.6
15 psoriatic juvenile idiopathic arthritis 11.5
16 pauciarticular chronic arthritis 11.3
17 juvenile ankylosing spondylitis 10.4
18 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.4
19 rheumatoid factor-negative juvenile idiopathic arthritis with anti-nuclear antibodies 10.4
20 familial mediterranean fever 10.3
21 leukemia, acute lymphoblastic 10.3
22 lymphocytic leukemia 10.3
23 macrophage activation syndrome 10.3
24 photokeratitis 10.3 MIF IL6
25 cysticercosis 10.2 MIF IL6
26 anca-associated vasculitis 10.2 IL6 HLA-DRB1
27 central nervous system vasculitis 10.2 IL6 HLA-DRB1
28 psoriatic arthritis 10.2
29 cystic echinococcosis 10.2 IL6 HLA-DRB1
30 echinococcosis 10.2 IL6 HLA-DRB1
31 disseminated intravascular coagulation 10.2
32 dengue shock syndrome 10.2 IL6 HLA-DRB1
33 idiopathic neutropenia 10.1 IL6 HLA-DRB1
34 rheumatic fever 10.1 IL6 HLA-DRB1
35 diffuse cutaneous systemic sclerosis 10.1 MIF HLA-DRB1
36 neuromyelitis optica 10.1 IL6 HLA-DRB1
37 ocular cicatricial pemphigoid 10.1 MIF HLA-DRB1
38 uveitis 10.1
39 hemorrhagic fever with renal syndrome 10.1 IL6 HLA-DRB1
40 exanthem 10.1
41 thrombocytosis 10.1
42 radiculopathy 10.1 IL6 IL1R1
43 rheumatic heart disease 10.1 IL6 HLA-DRB1
44 post-transplant lymphoproliferative disease 10.1 IL6 IL1R1
45 dengue hemorrhagic fever 10.1 IL6 HLA-DRB1
46 autoimmune disease of central nervous system 10.0 IL6 HLA-DRB1
47 spondyloarthropathy 1 10.0
48 renal cell carcinoma, nonpapillary 10.0
49 ige responsiveness, atopic 10.0
50 keratitis, hereditary 10.0

Graphical network of the top 20 diseases related to Rheumatoid Arthritis, Systemic Juvenile:



Diseases related to Rheumatoid Arthritis, Systemic Juvenile

Symptoms & Phenotypes for Rheumatoid Arthritis, Systemic Juvenile

Human phenotypes related to Rheumatoid Arthritis, Systemic Juvenile:

59 32 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
2 joint swelling 59 32 hallmark (90%) Very frequent (99-80%) HP:0001386
3 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
4 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
5 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
6 elevated c-reactive protein level 59 32 hallmark (90%) Very frequent (99-80%) HP:0011227
7 elevated erythrocyte sedimentation rate 59 32 hallmark (90%) Very frequent (99-80%) HP:0003565
8 juvenile rheumatoid arthritis 59 32 hallmark (90%) Very frequent (99-80%) HP:0005681
9 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
10 splenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001744
11 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
12 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
13 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
14 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
15 anterior uveitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012122

Clinical features from OMIM:

604302

Drugs & Therapeutics for Rheumatoid Arthritis, Systemic Juvenile

Drugs for Rheumatoid Arthritis, Systemic Juvenile (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 4 58-05-9 143 6006
3
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
10
Histamine Approved, Investigational Phase 4 51-45-6 774
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Famotidine Approved Phase 4 76824-35-6 3325
13
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
14
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
15
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
17
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
18 Immunologic Factors Phase 4
19 Folic Acid Antagonists Phase 4
20 Vitamin B9 Phase 4
21 Immunosuppressive Agents Phase 4
22 Folate Phase 4
23 Vitamin B Complex Phase 4
24 Dermatologic Agents Phase 4
25 Nucleic Acid Synthesis Inhibitors Phase 4
26 Antimetabolites Phase 4
27 Antimetabolites, Antineoplastic Phase 4
28 Cyclooxygenase Inhibitors Phase 4
29 Antiemetics Phase 4
30 Prednisolone acetate Phase 4
31 Neuroprotective Agents Phase 4
32 Methylprednisolone Acetate Phase 4
33 Protective Agents Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Autonomic Agents Phase 4
36 Antacids Phase 4
37 Proton Pump Inhibitors Phase 4
38 Anti-Ulcer Agents Phase 4
39 Vaccines Phase 4
40
Histamine Phosphate Phase 4 51-74-1 65513
41 Histamine Antagonists Phase 4
42 Histamine H2 Antagonists Phase 4
43 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
44 Pharmaceutical Solutions Phase 4
45 Neurotransmitter Agents Phase 4
46 Adrenergic alpha-2 Receptor Agonists Phase 4
47 Adrenergic Agonists Phase 4
48 Adrenergic alpha-Agonists Phase 4
49 Central Nervous System Depressants Phase 4
50 Adrenergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 212)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
3 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
4 A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis. Completed NCT00807846 Phase 4 Celecoxib;Naproxen
5 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
6 A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4 VIMOVO 250/20;VIMOVO 375/20;VIMOVO 500/20
7 Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA) Completed NCT00443430 Phase 4 methotrexate;methotrexate - etanercept - prednisolone arm
8 A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4 800 mg ibuprofen/26.6 mg famotidine
9 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
10 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
11 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
12 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4 Dexmedetomidine;Sedatives/Hypnotics,Other
13 A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis Recruiting NCT03301883 Phase 4 Tocilizumab;NSAIDs;CSs;MTX
14 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Active, not recruiting NCT00573651 Phase 4
15 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Active, not recruiting NCT01734382 Phase 4 Tocilizumab
16 An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4 Sulfasalazine
17 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
18 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
19 An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02396212 Phase 3
20 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
21 β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT02296424 Phase 3 ACZ885 150 mg (Canakinumab)
22 ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS) Completed NCT00339157 Phase 2, Phase 3 Anakinra
23 Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3 Celecoxib;Celecoxib;Naproxen
24 Childhood Onset Psychiatric Disorders: A Placebo Controlled Double-Blind Crossover Trial of Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
25 A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis Completed NCT00034853 Phase 3 meloxicam oral suspension;naproxen oral suspension
26 A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis Completed NCT00962741 Phase 3 Etanercept
27 An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA Completed NCT00144664 Phase 3 MRA(Tocilizumab)
28 A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA Completed NCT00144599 Phase 3 MRA(Tocilizumab);placebo
29 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
30 A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Completed NCT00889863 Phase 3 canakinumab;placebo
31 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP Completed NCT00144625 Phase 3 MRA(Tocilizumab)
32 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP Completed NCT00144612 Phase 3 MRA(Tocilizumab)
33 A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis Completed NCT01166282 Phase 3
34 A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics Completed NCT01835470 Phase 3 Abatacept
35 Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA) Completed NCT00775437 Phase 3 Adalimumab
36 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977) Completed NCT01673919 Phase 3 tocilizumab [RoActemra/Actemra]
37 A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis Completed NCT00690573 Phase 3
38 Effect of Supplementation With 2000 International Units (IU) Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis Completed NCT00570934 Phase 3 Placebo
39 Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977) Completed NCT01727986 Phase 3 tocilizumab [RoActemra/Actemra]
40 Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977) Completed NCT01667471 Phase 3 tocilizumab [RoActemra/Actemra]
41 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis. Completed NCT00279747 Phase 3 meloxicam 0.25 mg/kg;meloxicam 0.125 mg/kg;naproxen 10 mg/kg
42 A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis Completed NCT00036374 Phase 3 Infliximab
43 Safety, Population Pharmacokinetics, and Efficacy of Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) in Children With Juvenile Rheumatoid Arthritis Completed NCT03780959 Phase 2, Phase 3 Etanercept;Placebo
44 A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
45 A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA) Completed NCT00095173 Phase 3 Abatacept;Placebo;Abatacept
46 An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever Completed NCT00891046 Phase 3 Canakinumab
47 A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
48 Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development Completed NCT00420251 Phase 3 Genotropin
49 Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial. Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone
50 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Completed NCT00048542 Phase 3 OLE BSA Adalimumab +/- MTX;OLE FD Adalimumab +/- MTX

Search NIH Clinical Center for Rheumatoid Arthritis, Systemic Juvenile

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Tetracosactide

Cochrane evidence based reviews: arthritis, juvenile

Genetic Tests for Rheumatoid Arthritis, Systemic Juvenile

Genetic tests related to Rheumatoid Arthritis, Systemic Juvenile:

# Genetic test Affiliating Genes
1 Rheumatoid Arthritis, Systemic Juvenile 29 IL6 MIF

Anatomical Context for Rheumatoid Arthritis, Systemic Juvenile

MalaCards organs/tissues related to Rheumatoid Arthritis, Systemic Juvenile:

41
Bone, Liver, Skin, Testes, Brain

Publications for Rheumatoid Arthritis, Systemic Juvenile

Articles related to Rheumatoid Arthritis, Systemic Juvenile:

(show all 34)
# Title Authors PMID Year
1
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. 8 71
12746913 2003
2
A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. 8 71
11508429 2001
3
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. 8 71
9769329 1998
4
Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. 71
17623760 2007
5
Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. 8
17362866 2007
6
Interleukin-6 involvement in brain arteriovenous malformations. 71
16278864 2006
7
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. 71
16150725 2005
8
Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. 71
15331795 2004
9
Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. 71
15472205 2004
10
Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. 71
15070960 2004
11
Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. 71
12719374 2003
12
The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. 71
12560873 2003
13
Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. 71
12519862 2003
14
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. 8
12355488 2002
15
The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. 71
11889177 2002
16
An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. 71
11001912 2000
17
Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. 71
10720087 2000
18
Juvenile rheumatoid arthritis as a complex genetic trait. 8
10555018 1999
19
Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. 8
8923378 1996
20
Inflammatory cytokine responses in juvenile chronic arthritis. 8
7788176 1995
21
Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. 8
1767079 1991
22
IL-6: from its discovery to clinical applications. 9 38
20410258 2010
23
Interleukin 6: from bench to bedside. 9 38
17075601 2006
24
Tocilizumab (Actemra). 38
28841363 2017
25
A new alternative therapy in dermatology: tocilizumab. 38
26023856 2016
26
The biology and medical implications of interleukin-6. 38
24764575 2014
27
A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. 38
24594001 2014
28
Impact of interleukin-6 in hematological malignancies. 38
24273487 2013
29
[Medical study of 69 cases diagnosed as Kikuchi's disease]. 9
19697871 2009
30
Blockade of interleukin 1 receptor in Still's disease affects activation of peripheral T-lymphocytes. 9
19143047 2008
31
Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? 9
9489807 1998
32
Still's disease in children and adults: a distinct pattern of acute-phase proteins. 9
9694067 1998
33
Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. 9
9045866 1997
34
Relationship between interleukin-6 levels and platelet counts in systemic juvenile rheumatoid arthritis: comment on the article by De Benedetti et al. 9
1622424 1992

Variations for Rheumatoid Arthritis, Systemic Juvenile

ClinVar genetic disease variations for Rheumatoid Arthritis, Systemic Juvenile:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MIF MIF, -173G-C single nucleotide variant risk factor
2 IL6 IL6, -174G-C single nucleotide variant risk factor

Expression for Rheumatoid Arthritis, Systemic Juvenile

Search GEO for disease gene expression data for Rheumatoid Arthritis, Systemic Juvenile.

Pathways for Rheumatoid Arthritis, Systemic Juvenile

Pathways related to Rheumatoid Arthritis, Systemic Juvenile according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 SERPINA3 MIF IL6 IL2RB IL1R1 HLA-DRB1
2
Show member pathways
12.92 IL6 IL2RB IL1R1 HLA-DRB1
3
Show member pathways
11.88 MIF IL6 IL1R1
4
Show member pathways
11.79 IL6 IL2RB IL1R1 HLA-DRB1
5
Show member pathways
11.67 IL6 IL2RB IL1R1
6 11.58 MIF IL6 IL1R1
7 11.56 IL6 IL1R1
8 11.5 IL6 HLA-DRB1
9
Show member pathways
11.49 IL2RB IL1R1 HLA-DRB1
10 11.43 IL2RB IL1R1
11 11.32 IL6 IL1R1 HLA-DRB1
12
Show member pathways
11.29 MIF IL6
13 11.26 IL6 IL2RB IL1R1 HLA-DRB1
14 11.15 IL6 IL1R1
15 10.83 IL6 HLA-DRB1

GO Terms for Rheumatoid Arthritis, Systemic Juvenile

Cellular components related to Rheumatoid Arthritis, Systemic Juvenile according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.13 IL2RB IL1R1 HLA-DRB1
2 cell surface GO:0009986 8.92 MIF IL2RB IL1R1 HLA-DRB1

Biological processes related to Rheumatoid Arthritis, Systemic Juvenile according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.54 IL6 IL1R1 HLA-DRB1
2 cytokine-mediated signaling pathway GO:0019221 9.33 IL6 IL2RB IL1R1
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.32 MIF IL6
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.26 MIF IL6
5 acute-phase response GO:0006953 8.96 SERPINA3 IL6
6 inflammatory response GO:0006954 8.92 SERPINA3 MIF IL6 IL1R1

Sources for Rheumatoid Arthritis, Systemic Juvenile

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....